FORM OF INDEMNITY AGREEMENTIndemnity Agreement • June 9th, 2021 • Innovatus Life Sciences Acquisition Corp. • Blank checks • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of , 2021, by and between Innovatus Life Sciences Acquisition Corp., a Delaware corporation (the “Company”), and (“Indemnitee”).
INVESTMENT MANAGEMENT TRUST AGREEMENTInvestment Management Trust Agreement • April 6th, 2021 • Innovatus Life Sciences Acquisition Corp. • Blank checks • New York
This Investment Management Trust Agreement (this “Agreement”) is made effective as of [ ], 2021 by and between Innovatus Life Sciences Acquisition Corp., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Trustee”).
17,500,000 Shares of Class A Common Stock Innovatus Life Sciences Acquisition Corp. UNDERWRITING AGREEMENTUnderwriting Agreement • June 9th, 2021 • Innovatus Life Sciences Acquisition Corp. • Blank checks • New York
The Company has entered into an Investment Management Trust Agreement, dated as of the date hereof, with Continental Stock Transfer & Trust Company (“CST”), as trustee, in substantially the form filed as Exhibit 10.2 to the Registration Statement (the “Trust Agreement”), pursuant to which certain of the proceeds from the sale of the Private Placement Shares (as defined below) and the proceeds of the Offering will be deposited and held in a trust account (the “Trust Account”) for the benefit of the Company, the Underwriters and the holders of the Underwritten Securities and the Option Securities, if and when issued.
Innovatus Life Sciences Acquisition Corp. New York, New York 10017Innovatus Life Sciences Acquisition Corp. • March 5th, 2021 • Blank checks • New York
This agreement (the “Agreement”) is entered into on the date hereof by and between Innovatus Life Sciences Acquisition Sponsor, LLC, a Delaware limited liability company (the “Subscriber” or “you”) and Innovatus Life Sciences Acquisition Corp., a Delaware corporation (the “Company”, “we” or “us”). Pursuant to the terms hereof, the Company hereby accepts the offer the Subscriber has made to purchase 5,031,250 shares of Class B common stock, $0.0001 par value per share (the “Shares”), up to 656,250 of which are subject to forfeiture by you if the underwriters of the initial public offering (“IPO”) of shares of Class A common stock of the Company, do not fully exercise their over-allotment option (the “Over-allotment Option”). The Company and the Subscriber’s agreements regarding such Shares are as follows:
Innovatus Life Sciences Acquisition Corp. 777 Third Avenue, 25th Floor New York, New York 10017 Re: Initial Public Offering Ladies and Gentlemen:Letter Agreement • April 6th, 2021 • Innovatus Life Sciences Acquisition Corp. • Blank checks
This letter (this “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and among Innovatus Life Sciences Acquisition Corp., a Delaware corporation (the “Company”), and UBS Securities LLC as representative (the “Representative”) of the several underwriters (each, an “Underwriter” and collectively, the “Underwriters”), relating to an underwritten initial public offering (the “Public Offering”), of up to 20,125,000 shares of the Company’s Class A common stock, par value $0.0001 per share (including 2,625,000 shares of Class A common stock that may be purchased to cover over-allotments, if any) (the “Class A Common Stock”). The Class A Common Stock will be sold in the Public Offering pursuant to a registration statement on Form S-1 and prospectus (the “Prospectus”) filed by the Company with the U.S. Securities and Exchange Commission (the “Commission”) and the Company has applied to have the Class A Commo
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • June 9th, 2021 • Innovatus Life Sciences Acquisition Corp. • Blank checks • New York
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [ ], 2021, is made and entered into by and among Innovatus Life Sciences Acquisition Corp., a Delaware corporation (the “Company”), Innovatus Life Sciences Acquisition Sponsor, LLC, a Delaware limited liability company (the “Sponsor”) and the undersigned parties listed on the signature page hereto under “Holders” (each such party, together with the Sponsor and any person or entity who hereafter becomes a party to this Agreement pursuant to Section 5.02 of this Agreement, a “Holder” and collectively the “Holders”).
Innovatus Life Sciences Acquisition Corp. 777 Third Avenue, 25th Floor New York, NY 10017Innovatus Life Sciences Acquisition Corp. • June 9th, 2021 • Blank checks • Delaware
Innovatus Life Sciences Acquisition Corp., a Delaware corporation (the “Company”, “we” or “us”), is pleased to accept the offer made by Innovatus Life Sciences Acquisition Sponsor, LLC, a Delaware limited liability company (“Subscriber” or “you”), to purchase 585,000 shares (or 637,500 shares if the over-allotment option in connection with the IPO (as defined below) is exercised in full) (the “Shares”) of Class A common stock of the Company, $0.0001 par value per share (“Class A Common Stock”), at a price of $10.00 per share concurrently with the Company’s initial public offering (“IPO”). The terms of the sale by the Company of the Shares to Subscriber, and the Company and Subscriber’s agreements regarding the Shares, are as follows:
SUBSCRIPTION AGREEMENTSubscription Agreement • April 6th, 2021 • Innovatus Life Sciences Acquisition Corp. • Blank checks • New York
THIS AGREEMENT (this “Agreement”), is dated as of April 6, 2021, by and between Innovatus Life Sciences Acquisition Corp., a Delaware corporation (the “Company”), and Riverview Group II, Ltd. (“Subscriber”).
INNOVATUS LIFE SCIENCES ACQUISITION CORP. New York, NY 10017Letter Agreement • April 6th, 2021 • Innovatus Life Sciences Acquisition Corp. • Blank checks • New York
This letter agreement (this “Agreement”) by and between Innovatus Life Sciences Acquisition Corp. (the “Company”) and Innovatus Life Sciences Acquisition Sponsor, LLC (the “Sponsor”), dated as of the date hereof, will confirm our agreement that, commencing on the date the securities of the Company are first listed on The Nasdaq Capital Market (the “Listing Date”), pursuant to a Registration Statement on Form S-1 and prospectus filed with the Securities and Exchange Commission (the “Registration Statement”) and continuing until the earlier of the consummation by the Company of an initial business combination or the Company’s liquidation (in each case as described in the Registration Statement) (such earlier date hereinafter referred to as the “Termination Date”):
